American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

Published on by AHNS Webmaster

Congratulations 2020 Margaret F. Butler Outstanding Mentor of Women in Head and Neck Surgery Award Winner

The 2020 Margaret F. Butler   Mentor of Women in Head and Neck Surgery Award Winner
Dr. Cherie-Ann Nathan
Ahead of the AHNS 10th International Conference on Head and Neck Cancer, we pay tribute to the 2020 Winner of the Margaret Butler Outstanding Mentor of Women in Head and Neck Surgery – Dr. Cherie-Ann Nathan.

Named in honor of Dr. Butler, the first woman chair of Otolaryngology-Head and Neck Surgery in the United States, this award recognizes individuals with significant impact and measurable outcomes in the mentorship of women in head and neck surgery. Dr. Nathan has had a great impact on the careers and lives of countless individuals in our specialty. She is a deserving and fitting winner of this Award and we are grateful for her leadership in promoting equity, diversity and inclusion in AHNS.

 

Please join us, her family and friends, in congratulating Dr. Nathan!

VIEW VIDEO TRIBUTE  ON THIS LINK HERE

#BeLikeButler

Trinitia Cannon, MD
Chair, AHNS Women in Head and Neck Surgery Committee.

Shirley Y. Su, MBBS FRACS
Vice Chair, AHNS Women in Head and Neck Surgery Committee
Co-Chair, Margaret F. Butler Outstanding Mentor of Women in Head and Neck Surgery Award

Kelly Michelle Malloy, MD
Co-Chair, Margaret F. Butler Outstanding Mentor of Women in Head and Neck Surgery Award

Published on by AHNS Webmaster

Tomorrow! AHNS Webinar May 26, 2021 – Nerve Monitoring, Loss of Signal and Extent of Surgery

Nerve Monitoring, Loss of Signal and Extent of Surgery

From the AHNS Endocrine Section

Wednesday, May 26, 2021
4:00 PM PT/6:00 PM CT/7:00 PM ET

CME AVAILABLE

The American Head and Neck Society (AHNS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

The American Head and Neck Society (AHNS) designated this live activity for a maximum of 1 AMA PRA 1 Credit(s)TM. Physicians should claim only the credit they commensurate with the extent of their participation in the activity.

Registration: This Course is Free for AHNS members and $25.00 for non-AHNS-members.

Register Here

Published on by William Ryan, MD

Indications for preoperative imaging for high-risk cutaneous squamous cell carcinoma of the head and neck

By William R. Ryan, MD, University of California-San Francisco

Preoperative imaging for high-risk cutaneous squamous cell carcinoma (HRcSCC) of the head and neck lacks robust diagnosis-specific data regarding utility and lacks established guidelines regarding indications.  Ultimately, physicians can exercise their own preferences for imaging of patients with HRcSCC in order to evaluate 1) the extent of local invasion, 2) the possibility of regional metastases to the parotid and/or neck, and 3) the presence of distant metastases.  The following text outlines the definition of HRcSCC and some possible strategies for the choice of preoperative imaging for patients with HRcSCC of the head and neck.

“High-risk” features of cSCC are defined as those that are associated with increased risk of recurrence, increase risk of regional and/or distant metastasis, and/or increased risk disease-specific death.  High risk features of head and neck cSCC include the following:

Head and Neck Cutaneous Squamous Cell Carcinoma High-Risk Features1-4

Clinical:

  • Face, Ear, Lip subsites
  • H-Zone (mid-face at the sites of the embryologic fusion plates)
  • 2 cm+ (AJCC T2)
  • Recurrence
  • Immunosuppression:
    • Especially solid organ transplant, with increased risk with time since transplant
    • Also, especially chronic lymphocytic leukemia

Histopathology:

  • Perineural Invasion >0.1mm
  • Lymphovascular Invasion
  • >2mm Depth of Invasion
  • Invasion Beyond Fat
  • Bone Invasion
  • Subtype:
    • Poorly Differentiated
    • Acantholytic
    • Adenosquamous
    • Desmoplastic
    • Basosquamous
    • Spindle Cell

All of these factors, usually when multiple factors are present, increase the likelihood of recurrence.  Brigham and Womens’ stage T2b (defined as 2-3 of the following risk factors: tumor diameter ≥ 2 cm, poorly differentiated histology, depth of tumor invasion beyond fat, and/or perineural invasion ≥ 0.1 mm) has been shown to have a 21-30% risk of regional micrometastases, thereby indicating a significant risk for occult metastasis.5 Imaging can be considered when any of these features are found during a physical exam and/or incisional or excisional biopsies, especially if there are 2 or more of these features present.  If there is a palpable regional lymph node on physical exam, imaging should be performed with the plan for a fine needle aspiration biopsy to determine the presence of regional metastatic disease.

In HRcSCC patients, imaging has been shown, at least by one study6, to change management in one-third of patients and may even improve outcomes.  The HRcSCC patients who underwent imaging in this retrospective study had a significantly better 5-year disease-free survival rate compared to patients who did not (78% vs. 51%).  Thus, earlier identification and appropriate treatment intervention may improve oncologic outcomes for HRcSCC.

The specific choices of imaging modality depends on the clinical picture.  For the assessment of extent of local invasion, computed tomography (CT) head/neck with contrast can be performed when bone invasion is suspected while magnetic resonance imaging (MRI) head and neck with gadolinium can be performed when deep soft tissue and/or nerve invasion are suspected.  Although CT and MRI also provide fairly accurate and equivalent assessments of lymph node metastases, ultrasound and PET/CT have been shown to have a slightly superior accuracy for this function.7 Positron emission tomography (PET)/CT provides additional information about the presence or absence of distant metastases. However, insurance approvals for PET/CT in this setting can be challenging.

For lymph node metastasis assessment, the majority of studies that evaluate the utility and accuracy of head and neck imaging are in patients with mucosal SCC, not cutaneous SCC.  Cutaneous SCC are anatomically different with less predictable lymphatic spread patterns than mucosal SCC.  However, one can extrapolate the imaging characteristics of suspicious lymph nodes from head and neck mucosal SCC to cSCC of the head and neck.8  A review of 17 studies that each compared imaging assessments of neck lymph nodes to histopathologic findings in patients with head and neck aerodigestive SCC found that CT, MRI, and US all had fairly similar sensitivities, ranging from 80-87%, with US having the highest sensitivity.7  In cases of sub-centimeter sized lymph nodes, the following characteristics are associated with metastatic lymph nodes: irregular or intense enhancement, surrounding fat stranding, adherent or fused lymph nodes, asymmetry, and especially central necrosis.9-10

The following is an outline of the advantages and disadvantages of each imaging modality in the evaluation of HRcSCC:

Ultrasound (US)

US has the following advantages: 1) a more sensitive lymph node assessment compared to other modalities; 2) the least expensive modality; 3) poses no risks to the patient; 4) can be performed by the clinician in real time, which provides immediate dynamic information that can be discussed during a clinic visit.  US has the following disadvantages in having: 1) limited assessment of depth of invasion or invasion alone nerves; 2) no information of tissue in or deep to bone; and 3) no information about distant metastases.

Computed tomography (CT) head and/or neck

CT has the following advantages: 1) the most superior assessment for cortical bone invasion whether it be calvarium, temporal, mandible, maxilla, or spine boney structure; 2) a more rapid capture time than MRI; and 3) less expensive than MRI.  Disadvantages include: 1) poorer soft tissue delineation as compared to MRI; 2) radiation to the patient; and 3) iodinated contrast risks including allergic reaction and kidney damage.

Magnetic resonance imaging (MRI) head and neck

MRI has the following advantages: 1) superior evaluation of soft tissue, nerves, particularly for the parotid gland and facial nerve; 2) superior evaluation of the skullbase and brain; 3) a superior evaluation of bone marrow invasion; and 4) no irradiation risks.  Disadvantages include: 1) time of imaging capture; 2) expense; and 3) risk of claustrophobia and migration of metallic materials/retained foreign bodies.

Positron Emission Tomography/Computed Tomography (PET/CT)

PET/CT has the following advantages: 1) concurrent evaluation for lymph node and/or distant metastases; 2) for chronic lymphocytic leukemia, a PET/CT can help for the differentiation from lymphoma.  Disadvantages include: 1) increased dose of radiation compared to other modalities; 2) expense; and 3) increased risk of incidental and/or artifactual findings.

There is certainly some overlap in the capabilities of these modalities. Also, a combination of these modalities can be performed; however, attention to cost and time impact on the patient can be contributing factors for these decisions.

The author regularly performs ultrasound in the office setting, which often enables an immediate assessment of lymph nodes at the time of initial diagnosis and workup.  This assessment helps determine the need for same-day fine needle aspiration (FNA) of suspicious lymph nodes, helps inform the need for PET/CT if suspicious lymph nodes are present, and enhances discussions of stage and the extent of surgery with the patient in the same clinic encounter.

Conclusions

Imaging is important in the management of HRcSCC to evaluate the extent of local disease, to assess the presence of regional and/or distant metastases, and to guide management, such as the need for lymph node FNA, and planning the extent of surgery.  There is flexibility of choice of imaging modality for HRcSCC.  I have outlined some strategies for modality specific indications that are hopefully helpful.

References

  1. Fu T, Aasi SZ, Hollmig ST. Management of High-Risk Squamous Cell Carcinoma of the Skin. Curr Treat Options Oncol. 2016 Jul;17(7):34. doi: 10.1007/s11864-016-0408-2. PMID: 27262708.
  2. Combalia A, Carrera C. Squamous Cell Carcinoma: An Update on Diagnosis and Treatment. Dermatol Pract Concept. 2020 Jun 29;10(3):e2020066. doi: 10.5826/dpc.1003a66. PMID: 32642314; PMCID: PMC7319751.
  3. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018 Feb;78(2):249-261. doi: 10.1016/j.jaad.2017.08.058. PMID: 29332705.
  4. Humphreys TR, Shah K, Wysong A, Lexa F, MacFarlane D. The role of imaging in the management of patients with nonmelanoma skin cancer: When is imaging necessary? J Am Acad Dermatol. 2017 Apr;76(4):591-607. doi: 10.1016/j.jaad.2015.10.009. Erratum in: J Am Acad Dermatol. 2017 Jun;76(6):1226. PMID: 28325389.
  5. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014 Feb 1;32(4):327-34. doi: 10.1200/JCO.2012.48.5326. Epub 2013 Dec 23. PMID: 24366933; PMCID: PMC3897257.
  6. Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017 Feb;76(2):217-225. doi: 10.1016/j.jaad.2016.08.051. Epub 2016 Oct 1. PMID: 27707594.
  7. de Bondt RB, Nelemans PJ, Hofman PA, Casselman JW, Kremer B, van Engelshoven JM, Beets-Tan RG. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol. 2007 Nov;64(2):266-72. doi: 10.1016/j.ejrad.2007.02.037. Epub 2007 Mar 27. PMID: 17391885.
  8. Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, Lee IJ. CT, MR, US,18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2009 Mar;19(3):634-42. doi: 10.1007/s00330-008-1192-6. Epub 2008 Oct 9. PMID: 18843493.
  9. Som PM, Curtin HD, Mancuso AA. Imaging-based nodal classification for evaluation of neck metastatic adenopathy. AJR Am J Roentgenol. 2000 Mar;174(3):837-44. doi: 10.2214/ajr.174.3.1740837. PMID: 10701636.
  10. Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017 Feb;76(2):217-225. doi: 10.1016/j.jaad.2016.08.051. Epub 2016 Oct 1. PMID: 27707594.
  11. Navarrete-Dechent C, Veness MJ, Droppelmann N, Uribe P. High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review. J Am Acad Dermatol. 2015 Jul;73(1):127-37. doi: 10.1016/j.jaad.2015.03.039. PMID: 26089049.
William Ryan, MD

William Ryan, MD

Dr. William R. Ryan is associate professor of head and neck oncologic and endocrine surgery at University of California-San Francisco (UCSF). He completed medical school and otolaryngology-head and neck surgery residency at Stanford University and a head and neck oncologic surgery fellowship at UCSF. His research interests include post-treatment oncologic outcomes and patient-reported post-treatment quality of life outcomes for various head and neck cancers, especially for HPV+ oropharynx carcinoma.

Published on by AHNS Webmaster

AHNS Grants– Letter of Intent (LOI) Deadline: Tuesday, December 15, 2020 11:59 ET

Dear AHNS members,

The American Head and Neck Society will sponsor nine research grants for 2021 which are available through American Academy of Otolaryngology CORE. The Letters of Intent (LOI) for the Grants are due by 11:59 EST on Tuesday, December 15, 2020.

  1. AHNS.AAO-HNSF Young Investigator Combined Award – Open to fellows and assistant professors. Must be AHNS member (may be candidate member). To support research in neoplastic disease of the head and neck. Up to two years, $20,000 per year. One award available per year.
  2. AHNS/AAO-HNSF Translational Innovator Award – Applicants must have completed residency or fellowship training in seven years or less prior to submitting application. Candidates need to have demonstrated the capacity or potential for a highly productive independent research career with an emphasis in head and neck surgical oncology. Two years, non-renewable, $80,000 maximum ($40,000 per year), one available annually.
  3. AHNS Pilot Grant – Open to Medical Students, residents, PhD, and Junior Faculty residing in the U.S. or Canada to support basic, translational, or clinical research projects in head and neck oncology. One year, $10,000.00. One award available this year.
  4. AHNS Ballantyne Resident Research Pilot Grant – for best grant application by a resident, this award utilizes the same forms and guidelines as the pilot grant (above). One year, non-renewable, $10,000 maximum total costs. One award available per year. The top ranked pilot award will be honored as the Ballantyne Award.
  5. AHNS Endocrine Surgery Section Eisai Research Award – Open to medical students focusing in otolaryngology, otolaryngology residents, PhDs or faculty members in otolaryngology departments. Research topics must relate to endocrine surgery or disease. Preference will be given to early-stage investigators (10 years or less from a terminal degree or fellowship training) or more experienced researchers pursuing a new line of inquiry for which pilot data are needed. One year, $10,000.00. One award available this year.
  6. AHNS Endocrine Surgery Section Stryker Research Grant – Open to medical students focusing in otolaryngology, otolaryngology residents, PhDs or faculty members in otolaryngology departments. Research topics must relate to endocrine surgery or disease. Preference will be given to early-stage investigators (10 years or less from a terminal degree or fellowship training) or more experienced researchers pursuing a new line of inquiry for which pilot data are needed. One year, $10,000.00. One award available this year.
  7. AHNS Presidential Request for Application Pilot Award on Mucosal Head and Neck Cancer Research – Open to all otolaryngology-head and neck surgery residents, fellows, and faculty. Previous AHNS or AAO-HNS Foundation research grant recipients are eligible to compete for this grant. However, candidates who have successfully obtained funding from a private, institutional, or federal funding agency for the same research are ineligible. Candidates who have applied for support of the same research from other funding sources, and who are notified of an award from both another agency and from AHNS must choose only one of the awards. One year, $10,000. One award available.
  8. AHNS Presidential Request for Application Pilot Award on Salivary Gland Cancer Research – Open to active AHNS members, or trainees (ACGME-accredited otolaryngology residents or AHNS-accredited head and neck surgery fellows) sponsored by an AHNS member can apply. Previous AHNS or AAO-HNS Foundation research grant recipients are eligible to compete for this grant. However, candidates who have successfully obtained funding from a private, institutional, or federal funding agency for the same research are ineligible. Candidates who have applied for support of the same research from other funding sources, and who are notified of an award from both another agency and from AHNS must choose only one of the awards. One year, $10,000. One award available.
  9. AHNS Presidential Request for Application Pilot Award on Basic and Translational Research – This high risk, high reward grant is open to early or mid-career investigators who are AHNS members in good standing. Previous AHNS or AAO-HNS Foundation research grant recipients are eligible to compete for this grant. However, candidates who have successfully obtained funding from a private, institutional, or federal funding agency for the same research are ineligible. Candidates who have applied for support of the same research from other funding sources, and who are notified of an award from both another agency and from AHNS must choose only one of the awards. One year, $10,000. One award available.

You may find general information about the AHNS grants by visiting the website: https://www.ahns.info/research/grants/

Applicants interested in applying for the AHNS grants must submit their applications through the Academy CORE (combined otolaryngologic research evaluation) process. Letters of intent and applications are paperless and submitted through proposal Central.

Reminder: You must complete the Letter of Intent before submitting the full grant. You will not be penalized if you submit an LOI and decide not to complete a full grant.